✦ LIBER ✦

Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer

✍ Scribed by Jae Hong Seo; Yeul Hong Kim; Jun Suk Kim

Publisher: Springer
Year: 2008
Tongue: English
Weight: 254 KB
Volume: 63
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-008-0735-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of anastrozole versus tamoxif

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer : The pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial

✍ Luigi Cataliotti; Aman U. Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract ## BACKGROUND The Pre‐Operative “Arimidex” Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0‐2, M0), or potentially operable (T4b, N0‐2, M0) br

Optimizing aromatase inhibitor integrati

Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer

✍ Rowan T. Chlebowski 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 274 KB

Vitamin D intake may be a predictor of r

Vitamin D intake may be a predictor of response to aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer

✍ Omer Dizdar; Nilufer Bulut; Kadri Altundag 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 84 KB

Phase I/II study of sorafenib with anast

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

✍ Claudine Isaacs; Pia Herbolsheimer; Minetta C. Liu; Mary Wilkinson; Yvonne Ottav 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 220 KB

Cost-effectiveness of letrozole versus t

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective

✍ Thomas E. Delea; Khalid El-Ouagari; Jonathan Karnon; Oleg Sofrygin 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 301 KB

Do adjuvant aromatase inhibitors increas

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer : Meta-analysis of randomized trials

✍ Federica Cuppone; Emilio Bria; Sunil Verma; Kathleen I. Pritchard; Sonal Gandhi; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 1 views

## Abstract ## BACKGROUND. Despite the advantages from using aromatase inhibitors (AIs) compared with tamoxifen for early breast cancer, an unexpectedly greater number of grade 3 and 4 cardiovascular events (CVAE) (as defined by National Cancer Institute of Canada‐Common Toxicity Criteria [version